This page is for clinic owners and marketing teams producing website content, social media posts, or paid ads targeting Swiss patients. Switzerland’s advertising framework is layered — federal law, the FMH professional code, and cantonal rules stack on top of each other. Some cantons (Geneva, Ticino) are significantly stricter than the federal baseline. And if you advertise Botox or any prescription aesthetic product, a completely separate set of rules applies.
This page is especially relevant if you:
- advertise aesthetic, dental, dermatology, plastic surgery, or cosmetic services to Swiss patients
- use German-, French-, or Italian-language content targeting Switzerland
- translate clinic content into any Swiss language for the Swiss market
- advertise treatments involving botulinum toxin, fillers, or other prescription products
- work with influencers or clinic brand ambassadors for Swiss-market campaigns
- operate a clinic outside Switzerland that attracts Swiss patients
Unlike Germany’s HWG, Switzerland does not have a single medical advertising law. Doctor and clinic service advertising is governed by the Medical Professions Act (MedBG Art. 40d), which requires advertising to be objective, in the general interest, and neither misleading nor intrusive. The FMH Code of Deontology adds a stricter professional layer for FMH members. On top of that, cantons — particularly Geneva and Ticino — have their own advertising rules that go beyond the federal standard. And when the advertising also promotes a prescription medicine (such as botulinum toxin), Swissmedic’s therapeutic products rules take over.
Most problems in Swiss clinic marketing do not come from intentionally misleading content. They come from applying normal consumer marketing language — outcome promises, patient quotes, “best clinic” claims, before/after imagery — to a professional context where those patterns are treated as misleading or intrusive. Switzerland’s enforcement is not as centralised or aggressive as Germany’s, but cantonal authorities, FMH disciplinary bodies, and competitors can all trigger proceedings.
This page shows you the highest-risk phrases, what to replace them with, and where the grey areas are. It is a communication risk guide, not a legal compliance certification. Always verify specific cases with a qualified Swiss legal professional.
The Swiss Trigger Word List
These are the phrases most frequently at risk in Swiss medical advertising reviews. If any appear on your website or in your content, they are worth addressing first.
| What you wrote | Why it’s a problem | What to write instead |
|---|---|---|
| garantiert schmerzfrei / résultats garantis | Outcome guarantees are prohibited as misleading claims under MedBG Art. 40d and FMH Code Art. 20. No procedure can guarantee a pain-free or specific outcome for every patient. | schonende Methoden / méthodes douces — individuelle Ergebnisse variieren |
| risikofrei / sans risque / senza rischi | Risk-elimination claims are false — all medical procedures carry some level of risk. Treated as misleading advertising under MedBG and FMH standards. | minimal-invasiv / minimalement invasif — alle Risiken werden im Beratungsgespräch besprochen |
| beste Klinik der Schweiz / meilleure clinique de Suisse | Unverifiable superlatives are treated as advertising that “creates unjustified expectations” under FMH Annex 2, and as misleading commercial practice under Swiss UWG Art. 3. | spezialisiertes Team / équipe spécialisée en [Bereich] — erfahren seit [Jahr] |
| Botox (as a brand name in advertising) | Geneva official guidance explicitly prohibits using brand names such as “Botox” in aesthetic treatment advertising. Botulinum toxin is a prescription medicine — public advertising for prescription medicines is prohibited under Swiss therapeutic products law as enforced by Swissmedic. | Botulinum-Toxin-Behandlung / traitement au toxine botulique |
| Vorher-Nachher Bilder (botulinum toxin / aesthetic) | Geneva official guidance explicitly prohibits before/after images in botulinum toxin advertising. For other aesthetic procedures not involving prescription products, before/after imagery is high-risk if it implies guaranteed outcomes — but a Swiss-wide statutory ban for all aesthetic procedures is not fully verified from primary sources. | Klinikumgebung, Teamfotos, oder neutrale Behandlungsillustration |
| Patientin empfiehlt: “Endlich zufrieden!” / patient testimonial as ad content | FMH Annex 2 explicitly identifies patient recommendations as advertising that “impairs the standing of the profession.” Promotional testimonials are a clear red line for FMH members. | Link zur Google-Unternehmensseite oder zu einer unabhängigen Bewertungsplattform |
| Sonderpreis / prix spécial / offre limitée (for aesthetic procedures) | Geneva official guidance explicitly prohibits special price promotions in aesthetic treatment advertising (confirmed for botulinum toxin; high-risk for aesthetic services generally). FMH Annex 2 also flags advertising that encourages unnecessary or excessive care as improper. | Transparente Kosteninformation im Beratungsgespräch / information tarifaire disponible sur demande |
| Dr. [Name] — Spezialist für ästhetische Medizin (without verified official title) | Federal Supreme Court (2C_95/2021) confirmed that misleading use of academic titles and specialist wording on practice communications constitutes regulated advertising under MedBG Art. 40d. Non-official or inflated title claims are a specific enforcement risk. | Only use exact official titles (e.g., Facharzt FMH für Plastische Chirurgie) that you hold and can verify |
| pushy / marktschreierisch tone — “Jetzt buchen! Nur noch 3 Plätze!” | MedBG Art. 40d and FMH Code explicitly prohibit advertising that is “intrusive” (aufdringlich) in style. Urgency framing, aggressive CTAs, and high-pressure promotional tone are treated as intrusive regardless of factual accuracy. | Beratungsgespräch vereinbaren / prendre rendez-vous pour un entretien |
5 Real-World Rewrites — Before & After
One higher-risk example and one lower-risk rewrite for each procedure type. Written as real marketing copy — not sanitised legal examples.
Problems: outcome guarantee (“garantiert schmerzfrei”), unverifiable superlative (“beste Klinik Zürichs” — unjustified expectation under FMH Annex 2), intrusive promotional tone (“Jetzt buchen!”), free consultation as promotional incentive (high-risk in Geneva-style cantonal frameworks).
Why it’s lower risk: No outcome guarantee, no superlative, no promotional urgency. Price reference removed — costs are discussed in consultation. “Termin anfragen” is a neutral service function, not a promotional hook.
Problems: outcome guarantee (“garantiert”), unverifiable promotional statistic (“800 zufriedene Patienten” without cited source), self-praise framing — all create unjustified expectations under FMH Annex 2 and conflict with MedBG Art. 40d’s objectivity requirement.
Why it’s lower risk: “Realistisch erreichbare Ergebnisse” sets accurate expectations. No guarantee, no unverifiable statistic. The consultation is positioned as a genuine service, not a funnel entry.
Problems: “Botox” brand name prohibited in advertising (Geneva official guidance; Swissmedic prescription-product advertising rules), risk-elimination claim (“risikofrei”), before/after imagery (prohibited for botulinum toxin in Geneva; high-risk elsewhere), special price promotion (prohibited for aesthetic treatments under Geneva guidance).
Why it’s lower risk: Brand name replaced with generic term. No price promotion. No before/after imagery. No false safety assurance. Outcome variability explicitly acknowledged.
Problems: outcome overstatement (“löst das Problem”), inflated product claim (“revolutionäre”), patient testimonial used promotionally (explicitly prohibited by FMH Annex 2 as “Empfehlungen von Patienten”).
Why it’s lower risk: “Zugelassene” and “aktuellen Standard” are verifiable facts. No outcome promise. Testimonial removed entirely — passive review display on a third-party platform is a lower-risk alternative.
Problems: no commercial disclosure (Swiss UWG transparency requirement), “Botox” brand name in a promotional context (Swissmedic prescription-product advertising rules apply to influencers), before/after imagery (prohibited for botulinum toxin in Geneva; high-risk elsewhere), discount code (special price promotion prohibited for aesthetic treatments). The clinic is liable for content it commissioned.
Why it’s lower risk: Clear disclosure. No brand name for prescription product. No before/after content. No promotional pricing. Personal consultation experience, not outcome proof. The clinic controls the message and stays within objective, non-intrusive communication standards.
High-Risk Content — What Swiss Enforcement Has Actually Acted On
Some of these are explicit statutory or FMH code prohibitions. Others are confirmed by cantonal guidance or Swiss Federal Supreme Court case law. All are worth reviewing before your next campaign.
The risk: MedBG Art. 40d requires all physician advertising to be objective and non-misleading. FMH Code Art. 20 explicitly prohibits advertising based on untrue assertions or that creates unjustified expectations. Outcome guarantees, cure claims, and risk-elimination phrases fall squarely within this prohibition.
In practice: “Garantiert schmerzfrei,” “risikofrei,” “sicher und ohne Nebenwirkungen,” “geheilt in einer Sitzung” — all conflict with the objectivity requirement, regardless of how the claim is phrased or which Swiss language it appears in.
The risk: MedBG Art. 40d explicitly prohibits advertising that is “intrusive” (aufdringlich). FMH Annex 2 adds that advertising with a “self-promotional or market-crier style” (marktschreierische Darstellung) impairs the standing of the medical profession. This covers tone and format, not just specific words.
In practice: High-pressure urgency language (“Nur noch 3 Plätze!”), aggressive CTAs, excessive promotional punctuation or emoji formatting, “Act now” framing — all carry risk even when the underlying factual content is accurate.
The risk: FMH Annex 2 explicitly states that advertising “impairs the standing of the profession in particular if it includes recommendations from patients.” This is one of the clearest prohibitions in the Swiss framework — not an inference, but a direct statement in the FMH professional code.
In practice: Patient quotes, thank-you letters, video testimonials, or star-rating features used on clinic websites or in campaigns are high-risk for FMH members. Passive display of reviews on a third-party platform (Google Business, etc.) is a lower-risk alternative.
The risk: Botulinum toxin and many injectable aesthetic products are prescription medicines. Swiss therapeutic products law — enforced by Swissmedic — prohibits public advertising for prescription medicines. This applies not just to pharmaceutical companies but to all actors promoting such medicines publicly, including clinics and influencers. Swissmedic states it actively monitors print, electronic media, and social media.
In practice: Any post, ad, or website page that promotes a treatment using a prescription product by name, promotes the product’s effects, or features before/after results for that treatment is likely to be caught by this prohibition. Swissmedic refers serious or repeated cases to its Penal Division.
The risk: Geneva’s official aesthetic treatment guidance explicitly prohibits using brand names such as “Botox” in aesthetic advertising. Because botulinum toxin is a prescription medicine, any promotional use of the brand name conflicts with Swissmedic’s prescription-product advertising prohibition.
In practice: Replace “Botox” with the generic term “Botulinum-Toxin-Behandlung” / “traitement au toxine botulique” in all clinic advertising content, social media, and website copy. This applies across all three language regions.
The risk: The Federal Supreme Court confirmed in 2C_95/2021 that misleading use of “Dr.” and specialist wording on practice signage, letterheads, and websites constitutes regulated advertising under MedBG Art. 40d. Using non-official titles or implying specialist qualifications you do not hold is a primary enforcement trigger.
In practice: Only use exact, officially recognised titles (e.g., “Facharzt FMH für Plastische Chirurgie”) that you actually hold. The case confirmed that even a mailbox label or practice sign can be regulated advertising if it creates a misleading impression about qualifications.
The risk: Geneva official guidance explicitly prohibits before/after images in botulinum toxin advertising. For other aesthetic medical procedures, a Swiss-wide statutory ban could not be fully verified from primary sources — but such imagery remains high-risk if it creates unjustified expectations about outcomes or is presented in a promotional rather than factual context.
In practice: The safest approach is to remove before/after content from all promotional aesthetic advertising, not only for botulinum toxin. If you operate in Geneva or target Geneva-based patients, the prohibition on before/after imagery for botulinum toxin advertising is confirmed. For other cantons and other procedure types, treating this as high-risk is the prudent position.
The Grey Areas — Allowed Under Specific Conditions
These content types are not outright banned — but the details determine whether they create risk.
Allowed if: Pricing is presented as transparent, factual information — a neutral fee orientation rather than a promotional message. FMH and Geneva guidance allow factual service information including costs. Stating “Rhinoplastik ab CHF 3’500” as factual information is not per se prohibited.
Crosses the line if: Pricing is framed as a special offer, discount, or limited promotion for aesthetic treatments. Geneva explicitly prohibits special price promotions for aesthetic procedures. Any pricing combined with urgency framing (“Sonderpreis nur diese Woche”) is high-risk.
Allowed if: Statistics come from a peer-reviewed, citable source. Presented as population-level data with the source linkable and named. Does not imply an individual guarantee.
Crosses the line if: Used as a promotional outcome claim without a verifiable source (“95% unserer Patienten sind zufrieden”). Under FMH Annex 2, advertising that creates unjustified expectations is prohibited — unverified statistics are the most common way this happens.
Allowed if: A purely functional, neutral booking invitation — “Beratungsgespräch vereinbaren” or “Termin anfragen” — accompanying objective factual information about the clinic or procedure.
Crosses the line if: The CTA is embedded in promotional, intrusive, or misleading content. MedBG Art. 40d’s prohibition on intrusive advertising means the CTA inherits the risk profile of its surrounding content.
Allowed if: Commercial relationship clearly disclosed (Swiss UWG transparency requirement). Post content stays within the same objectivity and non-intrusiveness standards as the clinic’s own advertising. No prescription product brand names, no before/after imagery, no promotional pricing. Swissmedic’s social media guidance explicitly states that influencers promoting prescription medicines are subject to therapeutic-products advertising rules.
Crosses the line if: No disclosure. Post contains prescription product brand names, promotional pricing, or before/after content. The clinic is liable for content it commissioned — if the clinic cannot post it directly, the influencer cannot post it on the clinic’s behalf.
Allowed if: The award or certification is real, current, and verifiable. Named with a linkable source. Not used to imply superiority over competitors.
Crosses the line if: Used to make a superlative claim (“Switzerland’s most awarded aesthetic clinic”) or presented without a verifiable source. FMH Annex 2 prohibits advertising that creates unjustified expectations — unverifiable achievement claims fall within this category.
Important context: Geneva and Ticino have advertising rules that go beyond the federal MedBG baseline. Geneva explicitly prohibits: brand names for prescription products in aesthetic advertising, before/after images in botulinum toxin advertising, and special price promotions for aesthetic treatments. Ticino couples professional disciplinary sanctions with cantonal penal fines up to CHF 500,000 for serious intentional infringements. If your clinic is in or targeting patients in Geneva or Ticino, verify against cantonal rules specifically — the federal standard is not sufficient.
Practical note: The Swiss advertising regime is not three different systems by language region. A German-, French-, or Italian-language Swiss campaign follows Swiss federal law plus the cantons you are targeting — not German HWG, French CNOM, or Italian FNOMCeO.
The Cross-Border Trap for CEE Clinics
⚠ If your clinic is outside Switzerland and targeting Swiss patients — read this
Unlike Germany (HWG § 13), Switzerland does not have a verified statutory requirement for foreign clinics to appoint a Swiss representative in order to advertise into the country. However, Swiss Private International Law (IPRG Art. 136) states that unfair competition claims are governed by the law of the state “on whose market” the unfair act has its effect. A non-Swiss clinic targeting Swiss patients in German, French, or Italian may fall within Swiss unfair competition law if the advertising reaches and affects the Swiss market.
Additionally, if your advertising promotes treatments involving prescription products (botulinum toxin, certain injectable fillers), Swissmedic’s therapeutic-products advertising rules apply to anyone advertising those products to Swiss consumers — not only Swiss-based clinics. And if you are targeting Geneva-based patients, Geneva’s specific aesthetic advertising rules apply to that advertising regardless of where your clinic is based.
Reference: Swiss Rules Behind the Examples
Switzerland’s framework is layered — federal law, professional code, cantonal rules, and therapeutic products regulation all apply simultaneously depending on what you are advertising and where.
| Law / Code | What it covers | Enforcing authority | Max penalty |
|---|---|---|---|
| MedBG Art. 40d (Medical Professions Act) | All advertising by independently practising university medical professionals must be objective, in the general interest, non-misleading, and non-intrusive | Cantonal supervisory authorities (designated per canton) | Warning, reprimand, fine up to CHF 20,000, temporary ban up to 6 years, permanent ban |
| FMH Code of Deontology Art. 20 + Annex 2 | FMH member advertising rules — prohibits unsachlich, untrue, or reputation-damaging advertising; explicitly bans patient testimonials, unjustified-expectation messaging, and intrusive/market-crier style | FMH disciplinary bodies; cantonal medical societies | Reprimand, fine up to CHF 50,000, temporary suspension, expulsion, publication |
| HMG Arts. 31–32 + AWV/OPuM (Therapeutic Products Act) | Advertising of medicinal products including prescription aesthetic injectables — public advertising for prescription medicines is prohibited; all claims must match approved product information | Swissmedic (active monitoring of print, social media, online) | Administrative corrective procedures; serious/repeated cases referred to Swissmedic Penal Division |
| Swiss UWG Art. 3 para. 1 lit. b | General prohibition on misleading statements about oneself, one’s services, prices, or business relations — applies to all clinic entities regardless of physician status | Civil courts (injunction + damages); SECO (federal, for collective interests) | Civil injunction; damages; criminal complaint by SECO |
| Geneva Règlement sur les professions de la santé + RISanté | Cantonal rules for health professionals and institutions — objective advertising required; misleading content and overconsumption-encouraging advertising prohibited; explicit bans on Botox brand name, before/after images, and price promotions in aesthetic advertising | Geneva cantonal health authority | Professionals: fine up to CHF 20,000, temporary/permanent ban. Institutions: fine up to CHF 50,000, operating authorisation withdrawal |
| Ticino health law (LCA) Art. 70 + Art. 95 | Medical advertising must be objective, in the general interest, non-misleading, non-intrusive; prohibits referral/comparaggio arrangements; penal sanctions for health-law infringements | Ticino cantonal supervisory authority | Professional sanctions up to CHF 20,000 + ban; penal fines up to CHF 100,000 (serious: up to CHF 500,000) |
| Swiss IPRG Art. 136 (Private International Law Act) | Unfair competition claims governed by law of state where the unfair act has its market effect — applies Swiss law to foreign advertisers targeting Swiss consumers | Swiss civil courts | Civil injunction; damages |
Key enforcement case
Federal Supreme Court 2C_95/2021 (2021): The Court held that practice signage and mailbox labelling constitute “advertising” under MedBG Art. 40d where they are aimed at convincing patients of a practitioner’s medical competence. In this case, misleading use of “Dr.” and specialist wording on practice communications created a false impression about who led the practice and their qualifications. The Court upheld the finding of misleading advertising. This case is significant because it confirms that even the most modest practice communications — a nameplate, a letterhead — fall within Swiss medical advertising rules if they can mislead patients about qualifications.
Legal disclaimer: This page provides general information about Swiss medical advertising regulations for educational purposes only and does not constitute legal advice. Swiss regulations vary by canton and change over time. Verify all compliance requirements with a qualified Swiss legal professional before publishing any marketing materials. MedicalServiceFinder.com accepts no liability for decisions made based on this content.
Last updated: July 2026 | Primary sources: MedBG (fedlex.admin.ch); FMH Code of Deontology and Annex 2 (fmh.ch); HMG/AWV (fedlex.admin.ch); Swissmedic advertising guidance (swissmedic.ch); Geneva Règlement sur les professions de la santé (silgeneve.ch); Ticino health law (ti.ch); Swiss UWG (fedlex.admin.ch); IPRG Art. 136 (fedlex.admin.ch); Federal Supreme Court 2C_95/2021 (bger.ch)
